UNSPSC 51162729: Neltenexine

This classification denotes a mucolytic agent with the molecular formula C18H20Br2N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) U942DGM90X, chemically known as 4,6-dibromo-alpha-((trans-4-hydroxycyclohexyl)amino)-2-thiophene-carboxy-o-toluidide but more generally known as neltenexine, which bears US NIH Compound Identifier 3047787. European Medicines Agency schedules Neltenexine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09187MIG.

UNSPSC 51162729 Neltenexine is a Commodity code for pharmaceutical products, but the recent state and local solicitation activity tagged under this code reflects procurement of naloxone and safe drug deactivation systems for community health and emergency response, not the specific active pharmaceutical ingredient the code nominally describes. State and local governments buying under this code seek naloxone supply and related harm-reduction equipment for public health distribution, typically through county health departments and cooperative purchasing alliances. The issuing bodies include county health systems and multistate cooperative purchasing consortia administering pharmaceutical frameworks for participating state and local facilities. Vendors must meet standard pharmaceutical compliance requirements including current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, FDA compliance, and established relationships with authorized pharmaceutical wholesalers when the procurement flows through cooperative vehicles.

Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford, requiring bidders to include all shipping and delivery costs and comply with E-Verify and drug-free workplace certification. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with an RFP response deadline of March 26, 2026, serving state and local government facilities across participating jurisdictions including Oregon and requiring NDC-specific product information, cGMP and DSCSA compliance, and contractual relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC. Recent activity spans Florida and the Upper Midwest through cooperative purchasing structures, with emphasis on pharmaceutical supply chain integration and compliance-heavy vendor qualification.